Ldl Cholesterol

Monthly lerodalcibep on top of maximum tolerated therapy reduced LDL an additional 60% over 24 weeks in patients with heterozygous familial hypercholesterolemia, with a safety profile similar vs. placebo, a speaker reported.

Data show that higher cumulative remnant cholesterol and greater remnant cholesterol variability are each associated with elevated risk for atherosclerosis, independent of LDL, triglycerides level and other traditional CV risk factors.

Older adults derive greater LDL benefits after initiating statin therapy compared with younger adults, regardless of whether statins are prescribed for primary or secondary prevention or to people with diabetes, researchers reported.

An analysis of nearly 500 million cholesterol readings globally shows LDL levels vary widely by country and region even after adjusting for age and sex, suggesting population-specific interventions may be needed, researchers reported.

The FDA approved a label update for inclisiran to include people with elevated LDL and other risk factors such as hypertension and diabetes who have not experienced a CV event, Novartis announced.

Most U.S. adults with coronary artery disease are not meeting guideline-recommended LDL targets, even when prescribed statin therapy, according to an analysis of nationwide survey data.

Light to moderate alcohol consumption was associated with a reduced risk for major adverse cardiovascular events mediated by stress-related brain activity, according to findings published in the Journal of the American College of Cardiology.

PHILADELPHIA — LDL is a central component of CV risk reduction and data now show clear benefits of a sustained and substantial reduction, even in the setting of very high baseline LDL, according to a speaker.

In statin-treated patients with dyslipidemia, the combination of obicetrapib and ezetimibe further lowered LDL, according to the results of the phase 2 ROSE2 trial.